1. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85.
4. Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl 2011;124(192):5-15.
6. Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand Suppl 2011;124(192):36-47.
8. Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010;51:2423-31.
9. Riikonen R, Rener-Primec Z, Carmant L, Dorofeeva M, Hollody K, Szabo I, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015;57:60-7.
11. Plum J, Nohr MK, Hansen SH, Holm R, Nielsen CU. The anti-epileptic drug substance vigabatrin inhibits taurine transport in intestinal and renal cell culture models. Int J Pharm 2014;473:395-7.
12. Pearl PL, Vezina LG, Saneto RP, McCarter R, Molloy-Wells E, Heffron A, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009;50:184-94.
13. Dracopoulos A, Widjaja E, Raybaud C, Westall CA, Snead OC 3rd. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia 2010;51:1297-304.
14. Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009;50:206-16.
15. Jackson MC, Jafarpour S, Klehm J, Thome-Souza S, Coughlin F, Kapur K, et al. Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. Epilepsia 2017;58:1575-85.
16. Ohtsuka Y. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: primary short-term study and extension study. Epilepsy Behav 2018;78:134-41.
17. Schwarz MD, Li M, Tsao J, Zhou R, Wu YW, Sankar R, et al. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: the UCLA experience. Epilepsy Behav 2016;57(Pt A):29-33.
19. Cohen-Sadan S, Kramer U, Ben-Zeev B, Lahat E, Sahar E, Nevo Y, et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur J Neurol 2009;16:482-7.
20. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004;364:1773-8.
21. Gul Mert G, Herguner MO, Incecik F, Altunbasak S, Sahan D, Unal I. Risk factors affecting prognosis in infantile spasm. Int J Neurosci 2017;127:1012-8.
22. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004;45:1416-28.
23. Philippi H, Wohlrab G, Bettendorf U, Borusiak P, Kluger G, Strobl K, et al. Electroencephalographic evolution of hypsarrhythmia: toward an early treatment option. Epilepsia 2008;49:1859-64.
24. Eisermann MM, DeLaRaillere A, Dellatolas G, Tozzi E, Nabbout R, Dulac O, et al. Infantile spasms in Down syndrome: effects of delayed anticonvulsive treatment. Epilepsy Res 2003;55:21-7.
25. Wanigasinghe J, Arambepola C, Sri Ranganathan S, Sumanasena S, Muhandiram EC. The efficacy of moderate-to-high dose oral prednisolone versus low-to-moderate dose intramuscular corticotropin for improvement of hypsarrhythmia in West syndrome: a randomized, single-blind, parallel clinical trial. Pediatr Neurol 2014;51:24-30.